coumarin has been researched along with carbidopa in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Khoshroo, A; Mazloum-Ardakani, M | 1 |
Guerrero, MF; López, JL; Olaya, MDP; Vergel, NE; Viña, MD | 1 |
3 other study(ies) available for coumarin and carbidopa
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Nano composite system based on coumarin derivative-titanium dioxide nanoparticles and ionic liquid: determination of levodopa and carbidopa in human serum and pharmaceutical formulations.
Topics: Carbidopa; Carbon; Catalysis; Chemistry, Pharmaceutical; Coumarins; Electrochemical Techniques; Electrodes; Humans; Hydrogen-Ion Concentration; Ionic Liquids; Levodopa; Metal Nanoparticles; Nanocomposites; Oxidation-Reduction; Titanium | 2013 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Locomotion; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Reserpine | 2019 |